Ping Jiang

ORCID: 0000-0002-6247-4477 · 8 papers in corpus · active 2011-2018

Study types

  • article 8

Condition tags

  • endometriosis 8
  • chronic_pelvic_pain 2
  • adenomyosis 2
  • dysmenorrhea 1
  • dyspareunia 1
article 2018
Clinical Efficacy of GnRH-a in Patients with Moderate or Severe Endometriosis After Laparoscopic Surgery
article 2015
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study
·doi:10.5301/je.5000211

Purpose Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosis-associated pain. …

article 2014
Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114549848
article 2014
Serum differential proteomic analysis of endometriosis and adenomyosis by iTRAQ technique
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2014.08.034
article 2013
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Journal of endometriosis and pelvic pain disorders ·doi:10.5301/je.5000157

OBJECTIVE: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. METHODS: This was a phase II, randomized, placeb…

article 2013
Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719113497292
article 2013
Evaluation of novel serum biomarkers and the proteomic differences of endometriosis and adenomyosis using MALDI-TOF–MS
Archives of gynecology and obstetrics ·doi:10.1007/s00404-012-2700-0
article 2011
A novel oral GnRH antagonist, elagolix, is effective for reducing endometriosis-associated pelvic pain: results of a 24-week randomized study
·doi:10.1016/j.fertnstert.2011.07.171